Zevra Therapeutics, Inc. (FRA:1GDA)
Germany · Delayed Price · Currency is EUR | Market Cap | 700.77M +56.9% |
| Revenue (ttm) | 106.06M +201.3% |
| Net Income | 101.47M |
| EPS | 1.72 |
| Shares Out | n/a |
| PE Ratio | 6.91 |
| Forward PE | 14.43 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 11.45 |
| Previous Close | 11.35 |
| Day's Range | 11.45 - 11.45 |
| 52-Week Range | 6.05 - 11.85 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 11, 2026 |
About Zevra Therapeutics
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical tr... [Read more]
News
Zevra publishes Miplyffa data in Molecular Genetics, Metabolism Reports
Zevra Therapeutics (ZVRA) announced the publication of “Arimoclomol in infants with Niemann-Pick disease type C: Results from the phase 2/3 open-label pediatric substudy” in Molecular Genetics and Met...
Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)
Data published in Molecular Genetics and Metabolism Reports suggest MIPLYFFA (arimoclomol) was well tolerated in pediatric patients with no new safety signals observed Data published in Molecular Gene...
Zevra Therapeutics chief medical officer to step down
Zevra Therapeutics (ZVRA) announced that its chief medical officer, Adrian Quartel, will step down from his position due to personal reasons, effective July 3. Quartel will continue to support the…
Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition
BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living ...
Zevra Therapeutics price target raised to $35 from $25 at Maxim
Maxim analyst Jason McCarthy raised the firm’s price target on Zevra Therapeutics (ZVRA) to $35 from $25 and keeps a Buy rating on the shares.
Zevra Therapeutics price target raised to $29 from $25 at Guggenheim
Guggenheim raised the firm’s price target on Zevra Therapeutics (ZVRA) to $29 from $25 and keeps a Buy rating on the shares after the company announced that it submitted U.S.
Zevra Therapeutics price target raised to $27 from $23 at BTIG
BTIG raised the firm’s price target on Zevra Therapeutics (ZVRA) to $27 from $23 and keeps a Buy rating on the shares. The firm notes Zevra announced submission of U.S.
Zevra Therapeutics price target raised to $29 from $24 at Canaccord
Canaccord analyst Sumant Kulkarni raised the firm’s price target on Zevra Therapeutics (ZVRA) to $29 from $24 and keeps a Buy rating on the shares. The firm noted the company…
Zevra Therapeutics price target raised to $25 from $18 at Citizens
Citizens analyst Jason Butler raised the firm’s price target on Zevra Therapeutics (ZVRA) to $25 from $18 and keeps an Outperform rating on the shares. The company submitted an additional…
Zevra Therapeutics price target raised to $34 from $24 at Cantor Fitzgerald
Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on Zevra Therapeutics (ZVRA) to $34 from $24 and keeps an Overweight rating on the shares after the company announced…
Zevra Therapeutics announces Orange Book listing of Miplyffa patent
Zevra Therapeutics (ZVRA) announced that it has submitted U.S. Patent No. 11,707,456 for Miplyffa to the FDA for listing in the publication Approved Drug Products With Therapeutic Equivalence Evaluati...
Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA
MIPLYFFA patent submitted for Orange Book listing, with patent protection to 2041 Separately filed patent term extension remains pending with the U.S. Patent and Trademark Office BOSTON, June 08, 2026...
Zevra Therapeutics Slides: Corporate presentation
Zevra Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living w...
Zevra Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
A focused strategic plan has driven operational streamlining, a headquarters move to Boston, and targeted growth in both U.S. and global markets. AI-powered patient identification and robust regulatory progress support expanding access and pipeline acceleration, with variability in patient enrollment expected.
Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseas...
Zevra Therapeutics price target raised to $25 from $23 at Guggenheim
Guggenheim analyst Eddie Hickman raised the firm’s price target on Zevra Therapeutics (ZVRA) to $25 from $23 and keeps a Buy rating on the shares. The firm expects growth to…
Zevra Therapeutics reports Q1 EPS 60c, consensus 8c
Reports Q1 revenue $36.2M, consensus $31.96M. In Q1, the company received $40.5M of the $45M in net proceeds from the sale of the SDX portfolio. “Our results demonstrate the differentiated…
Zevra Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw 78% revenue growth, strong net income, and debt-free status driven by MIPLYFFA's U.S. launch and global expansion, SDX asset sale, and robust pipeline progress. MIPLYFFA now reaches about half of diagnosed U.S. NPC patients, with continued growth expected.
Zevra Therapeutics Earnings release: Q1 2026
Zevra Therapeutics released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Zevra Therapeutics Quarterly report: Q1 2026
Zevra Therapeutics has published its Q1 2026 quarterly earnings report on May 6, 2026.
Zevra Reports First Quarter 2026 Financial Results and Corporate Update
Q1 2026 net revenue of $36.2 million , a 78% increase over Q1 2025 Completed $50.0 million sale of SDX portfolio to Commave Therapeutics Operational execution fueled strong cash position of $236.8 mil...
Zevra Therapeutics Proxy statement: Proxy filing
Zevra Therapeutics filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Zevra Therapeutics Proxy statement: Proxy filing
Zevra Therapeutics filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Zevra Therapeutics Slides: Corporate presentation
Zevra Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 6, 2026.